What Neuspera’s 12-month iSNM trial data means for the sacral neuromodulation competitive landscape
Neuspera Medical’s 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.
Why BlueWind Medical’s latest FDA clearance matters for long-term urgency urinary incontinence care
BlueWind Medical secures FDA clearance for an enhanced Revi wearable. Find out why usability may define the next phase of neuromodulation adoption.